Acepodia, Inc. (6976.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$13.05 (-2.25%) as of
Key statistics
- Market cap
- 7.61B
- EPS (TTM)
- -1.37
- Dividend yield
- 0.00%
- 52-week range
- 10.85 – 17.40
- Beta
- 0.48
- Profit margin
- 0.00%
- Volume
- 472.65k
About Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Grand Cayman, Cayman Islands
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.